Call

Close

Endorsed By

Early detection with ForeseeHome

  • Wet AMD causes permanent vision loss if left undetected
  • Early detection is the best way to catch the progression from dry AMD to wet AMD
  • ForeseeHome is a simple, daily test that can help detect wet AMD earlier
    • Patients using ForeseeHome had a 94% rate of preserving driving vision (20/40 or better) at wet AMD diagnosis compared to 62% with standard methods of detection alone

Most people pay $0 Covered by Medicare and most insurance plans

Video demonstration Watch a video demonstration of the simple daily test

Download Brochure Get more information on AMD and ForeseeHome

ForeseeHome is an at-home monitoring device for the early detection of wet AMD

You take a simple, daily test to check for tiny changes in your vision

Monthly reports are sent directly to your doctor’s office. Testing results are available to your eye doctor 24/7 on the Notal Vision portal

If a change in test scores is detected, your doctor is alerted so an appointment can be scheduled

Learn more about ForeseeHome

Privacy Policy Notice of Privacy Practices Patents Disclaimer NotalVision.com Contact Us

FDA Indication for Use

The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration, as an aid in monitoring progression of disease factors causing metamorphopsia including but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

The ForeseeHome AMD Monitoring Program is only available by physician order and is intended to be used as an addition to regular eye exams.

The ForeseeHome AMD Monitoring Program is covered by Medicare, subject to its coverage requirements for the test, to assess patients with dry AMD who are at risk of developing wet AMD.